Ras inhibitors
US-2021130303-A1 · May 6, 2021 · US
Ras inhibitors
US11739074B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11739074-B2 |
| Application number | US-202017088848-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 4, 2020 |
| Priority date | Nov 4, 2019 |
| Publication date | Aug 29, 2023 |
| Grant date | Aug 29, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers. Exemplary Ras inhibitors include compounds of Formula I:
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of 2. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of claim 1 and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
Ketonic radicals · CPC title
with hetero atoms directly attached to the ring nitrogen atom · CPC title
Boronic and borinic acid compounds · CPC title
Acids; Esters · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11739074B2 cover?
- The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers. Exemplary Ras inhibitors include compounds of Formula I:
- Who is the assignee on this patent?
- Revolution Medicines Inc
- What technology area does this patent fall under?
- Primary CPC classification A61P35/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).